keyword
MENU ▼
Read by QxMD icon Read
search

Cabergolin

keyword
https://www.readbyqxmd.com/read/29928263/prolactin-producing-pituitary-carcinoma-hypopituitarism-and-graves-disease-report-of-a-challenging-case-and-literature-review
#1
Rita Bettencourt-Silva, Josué Pereira, Sandra Belo, Daniela Magalhães, Joana Queirós, Davide Carvalho
Introduction: The diagnosis of pituitary carcinoma is very rare, requires the evidence of metastatic disease, and has a poor overall survival. Malignant prolactinoma frequently requires dopamine agonist therapy, pituitary surgery, radiotherapy, and even chemotherapy. Case description: A 19-year-old female presented with galactorrhea, primary amenorrhea, and left hemianopsia. Complementary study detected hyperprolactinemia and a pituitary macroadenoma with cavernous sinus invasion and suprasellar growth...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29925553/analgesic-effect-of-long-acting-somatostatin-receptor-agonist-pasireotide-in-a-patient-with-acromegaly-and-intractable-headaches
#2
Christina M Lovato, Patricia L Kapsner
A 22-year-old woman presented with worsening vision loss and headaches. A diagnosis of acromegaly was confirmed after detection of an invasive pituitary macroadenoma and biochemical testing. Despite two attempts of surgical debulking of the tumour and administration of long-acting octreotide and cabergoline, growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were uncontrolled. The patient experienced persistent headaches despite surgery, gamma knife radiation and ventriculoperitoneal shunt placement; she was then enrolled in the ACCESS trial (ClinicalTrials...
June 19, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29896007/combined-cabergoline-and-metformin-in-patients-with-polycystic-ovarian-disease-with-hyperprolactinemia-methodological-concerns
#3
Ahmed Mohamed Abbas
No abstract text is available yet for this article.
June 2018: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/29870628/a-case-of-secondary-sunct-syndrome
#4
Gunay Gul, Melek Kandemir, Batuhan Kara, Nazan Karagoz Sakalli, Fulya Sengul Eren
SUNCT syndrome, a rare form of primary headaches, may be secondary to pituitary tumours. The secondary forms usually related with prolactinomas. The response of dopamin agonists could be variable. In this study, we reported a case of SUNCT syndrome secondary to prolactinoma. Cranial magnetic resonance imaging was performed for this patient because of the increase in pain severity and frequency. A hemorrhage was detected into the prolactinoma ipsilateral to the pain. The headache attacks were taken undercontrol and remission was ensured with cabergoline in a short time...
September 30, 2017: Ideggyógyászati Szemle
https://www.readbyqxmd.com/read/29860715/myasthenia-gravis-imitating-pituitary-apoplexy-in-macroprolactinoma
#5
REVIEW
Matteo Zoli, Federica Guaraldi, Marco Faustini, Diego Mazzatenta
Myasthenia gravis (MG) is an autoimmune disease affecting neuromuscular transmission that manifests with muscle weakness and typically involves the eye muscles, often producing diplopia and ptosis. Recent studies suggest that hyperprolactinaemia may have a role in the development of MG, although its association with prolactinoma is extremely rare. We report the unusual case of a 71-year-old male affected with macroprolactinoma, who presented at our Center 2 weeks after starting cabergoline treatment because of acute onset of headache, diplopia, and ptosis...
June 2, 2018: Hormones: International Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29768629/controversial-issues-in-the-management-of-hyperprolactinemia-and-prolactinomas-an-overview-by-the-neuroendocrinology-department-of-the-brazilian-society-of-endocrinology-and-metabolism
#6
Lucio Vilar, Julio Abucham, José Luciano Albuquerque, Luiz Antônio Araujo, Monalisa F Azevedo, Cesar Luiz Boguszewski, Luiz Augusto Casulari, Malebranche B C Cunha Neto, Mauro A Czepielewski, Felipe H G Duarte, Manuel Dos S Faria, Monica R Gadelha, Heraldo M Garmes, Andrea Glezer, Maria Helane Gurgel, Raquel S Jallad, Manoel Martins, Paulo A C Miranda, Renan M Montenegro, Nina R C Musolino, Luciana A Naves, Antônio Ribeiro-Oliveira Júnior, Cíntia M S Silva, Camila Viecceli, Marcello D Bronstein
Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both sexes. The magnitude of prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, PRL levels > 250 ng/mL are highly suggestive of the presence of a prolactinoma. In contrast, most patients with stalk dysfunction, drug-induced hyperprolactinemia or systemic diseases present with PRL levels < 100 ng/mL. However, exceptions to these rules are not rare...
March 2018: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29765354/pituitary-directed-therapies-for-cushing-s-disease
#7
REVIEW
Fabienne Langlois, Jennifer Chu, Maria Fleseriu
Cushing's disease (CD) is caused by a pituitary corticotroph neuroendocrine tumor inducing uncontrolled hypercortisolism. Transsphenoidal surgery is the first-line treatment in most cases. Nonetheless, some patients will not achieve cure even in expert hands, others may not be surgical candidates and a significant percentage will experience recurrence. Many patients will thus require medical therapy to achieve disease control. Pharmacologic options to treat CD have increased in recent years, with an explosion in knowledge related to pathophysiology at the molecular level...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29756335/treatment-of-restless-legs-syndrome-evidence-based-review-and-implications-for-clinical-practice-revised-2017-%C3%A2
#8
REVIEW
Juliane Winkelmann, Richard P Allen, Birgit Högl, Yuichi Inoue, Wolfgang Oertel, Aaro V Salminen, John W Winkelman, Claudia Trenkwalder, Cristina Sampaio
The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious...
May 14, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29746287/sexual-functioning-in-hyperprolactinemic-patients-treated-with-cabergoline-or-bromocriptine
#9
Robert Krysiak, Bogusław Okopień
BACKGROUND: Elevated prolactin levels were found to be associated with impaired sexuality. STUDY QUESTION: The aim of the study was to compare the impact of bromocriptine and cabergoline on sexual functioning in both genders. STUDY DESIGN: The study enrolled 39 young women and 18 young men receiving bromocriptine treatment. In 19 women and 8 men, because of poor tolerance, bromocriptine was replaced with cabergoline, whereas the remaining ones continued bromocriptine treatment...
May 1, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29736228/height-shape-and-anterior-posterior-diameter-of-pituitary-gland-on-magnetic-resonance-imaging-among-patients-with-multiple-sclerosis-compared-to-normal-individuals
#10
Mohammad Saba, Hossein Ali Ebrahimi, Habibeh Ahmadi-Pour, Mohammad Khodadoust
Background: Several studies indicate contribution of hypothalamus-pituitary-adrenal (HPA) axis in multiple sclerosis (MS) disease. This study was designed to determine whether there is an effective difference in pituitary height, shape, and anterior-posterior diameter (APD) between patients with MS and the control group. Methods: In this study, sagittal pituitary height and APD of 134 men and women (64 patients with MS and 70 healthy subjects as control group) were measured by T1 sequence magnetic resonance imaging (MRI)...
October 7, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29731299/dopamine-modulates-option-generation-for-behavior
#11
Yuen-Siang Ang, Sanjay Manohar, Olivia Plant, Annika Kienast, Campbell Le Heron, Kinan Muhammed, Michele Hu, Masud Husain
Animals make innumerable decisions every day, each of which involves evaluating potential options for action. But how are options generated? Although much is now known about decision making when a fixed set of potential options is provided, surprisingly little progress has been made on self-generated options. Some researchers have proposed that such abilities might be modulated by dopamine. Here, we used a new measure of option generation that is quantitative, objective, and culture fair to investigate how humans generate different behavioral options...
April 21, 2018: Current Biology: CB
https://www.readbyqxmd.com/read/29728863/igf-1-levels-may-increase-paradoxically-with-dopamine-agonist-treatment-for-prolactinomas
#12
Amit Akirov, Yona Greenman, Benjamin Glaser, Irena S'chigol, Yossi Mansiterski, Yoav Eizenberg, Ilana Shraga-Slutzky, Ilan Shimon
OBJECTIVE: Hyperprolactinemia is common in acromegaly and in these patients, insulin-like growth factor (IGF)-1 level may decrease with dopamine agonist. We report a series of patients with prolactinoma and a paradoxical increase of IGF-1 levels during cabergoline treatment. METHODS: Clinical characteristics and response to treatment of patients with prolactinomas, in whom normal or slightly elevated baseline IGF-1 levels increased with cabergoline. RESULTS: The cohort consisted of ten prolactinoma patients (nine males, mean age 48 ± 14 years)...
May 4, 2018: Pituitary
https://www.readbyqxmd.com/read/29726995/the-balance-of-pi3k-and-erk-signaling-is-dysregulated-in-prolactinoma-and-modulated-by-dopamine
#13
Allyson K Roof, Siwanon Jirawatnotai, Tammy Trudeau, Crystal Kuzyk, Margaret E Wierman, Hiroaki Kiyokawa, Arthur Gutierrez-Hartmann
Prolactin-secreting adenomas, or prolactinomas, cause hypogonadism, osteoporosis, and infertility. Although dopamine agonists (DAs) are used clinically to treat prolactinoma and reduce prolactin secretion via cAMP inhibition, the precise mechanism by which DAs inhibit lactotrope proliferation has not been defined. In this study, we report that phosphatidylinositol 3-kinase (PI3K) signals through AKT and mTOR to drive proliferation of pituitary somatolactotrope GH4T2 cells. We demonstrate that the DA cabergoline reduces activity of the mTOR effector s6K and diminishes GH4T2 cell proliferation primarily via activation of the long isoform of the dopamine D2 receptor (D2R)...
June 1, 2018: Endocrinology
https://www.readbyqxmd.com/read/29694638/a-review-of-cushing-s-disease-treatment-by-the-department-of-neuroendocrinology-of-the-brazilian-society-of-endocrinology-and-metabolism
#14
REVIEW
Márcio Carlos Machado, Maria Candida Barisson Vilares Fragoso, Ayrton Custódio Moreira, César Luiz Boguszewski, Leonardo Vieira Neto, Luciana A Naves, Lucio Vilar, Luiz Antônio de Araújo, Nina Rosa Castro Musolino, Paulo Augusto C Miranda, Mauro A Czepielewski, Monica R Gadelha, Marcello Delano Bronstein, Antônio Ribeiro-Oliveira
The treatment objectives for a patient with Cushing's disease (CD) are remission of hypercortisolism, adequate management of co-morbidities, restoration of the hypothalamic-pituitary-adrenal axis, preservation of fertility and pituitary function, and improvement of visual defects in cases of macroadenomas with suprasellar extension. Transsphenoidal pituitary surgery is the main treatment option for the majority of cases, even in macroadenomas with low probability of remission. In cases of surgical failure, another subsequent pituitary surgery might be indicated in cases with persistent tumor imaging at post surgical magnetic resonance imaging (MRI) and/or pathology analysis of adrenocorticotropic hormone-positive (ACTH+) positive pituitary adenoma in the first procedure...
February 2018: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29623588/recurrent-non-functioning-pituitary-adenomas-a-review-on-the-new-pathological-classification-management-guidelines-and-treatment-options
#15
REVIEW
P D Delgado-López, J Pi-Barrio, M T Dueñas-Polo, M Pascual-Llorente, M C Gordón-Bolaños
At least 50% of surgically resected non-functioning pituitary adenomas (NFPA) recur. Either early or late adjuvant radiotherapy is highly efficacious in controlling recurrent NFPA but associates potentially burdensome complications like hypopituitarism, vascular complications or secondary neoplasm. Reoperation is indicated in bulky tumor rests compressing the optic pathway. To date, no standardized medical therapy is available for recurrent NFPA although cabergoline and temozolomide show promising results. Guidelines on the management of recurrent NFPAs are now available...
April 5, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29614359/transient-splenial-lesion-of-the-corpus-callosum-after-cabergoline-treatment
#16
Hayri Ogul, Serhat Kaya, Yasemin Ogul
BACKGROUND: Transient splenial lesion of the corpus callosum is an oval-shaped lesion in the center of the splenium of the corpus callosum. The disease characteristically occurs with restricted diffusion-weighted images. CASE DESCRIPTION: In the present study, we describe the magnetic resonance imaging findings of a patient with transient diffusion restriction in the splenium of the corpus callosum after cabergoline therapy. CONCLUSIONS: Cabergoline may be an unusual cause of transient splenial lesion of corpus callosum...
June 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29569219/dopamine-d2-agonist-affects-visuospatial-working-memory-distractor-interference-depending-on-individual-differences-in-baseline-working-memory-span
#17
James M Broadway, Michael J Frank, James F Cavanagh
The interplay of dopaminergic striatal D1-D2 circuits is thought to support working memory (WM) by selectively filtering information that is to be remembered versus information to be ignored. To test this theory, we conducted an experiment in which healthy participants performed a visuospatial working memory (VSWM) task after ingesting the D2-receptor agonist cabergoline (or placebo), in a randomized, double-blinded, crossover design. Results showed greater interference from distractors under cabergoline, particularly for individuals with higher baseline dopamine (indicated by WM span)...
June 2018: Cognitive, Affective & Behavioral Neuroscience
https://www.readbyqxmd.com/read/29557627/-atypical-presentation-of-a-giant-prolactinoma-in-a-15-year-old-boy
#18
Elisa Vaiani, Cintia Morales, Florencia Soto, Yeny Blanco, Carlos Rugilo, Marta Ciaccio, Alicia Belgorosky
Giant prolactinomas are rare pituitary adenomas characterized by their great local invasion. In this paper, we report a 15-year-old male with left retro-ocular pain and ipsilateral exophthalmos of 4 months of evolution, secondary to a tumour in the base of the skull that invaded the orbit. Hormonal studies revealed serum prolactin of 6913,7 ng/ml (normal value < 20), confirming the diagnosis of giant prolactinoma. The patient started treatment with the dopaminergic agonist cabergoline in increasing doses...
April 1, 2018: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/29554822/evidence-for-the-involvement-of-the-dopaminergic-system-in-seizure-and-oxidative-damage-induced-by-tramadol
#19
Behnaz Bameri, Fatemeh Shaki, Nematollah Ahangar, Ramin Ataee, Mahedeh Samadi, Hamidreza Mohammadi
Tramadol (TR) is a synthetic analgesic drug with central function that can induce seizures even at therapeutic doses. The exact mechanism of TR effect on seizure generation is not clear, but inhibition of the serotonin and nitric oxide pathways and inhibitory effects on GABA receptors are the most common hypotheses about the seizure-inducing mechanism of the TR. This study aimed to evaluate the role of dopaminergic system on the seizure and oxidative damage induced by TR using agonist and antagonist drugs of this system in the Albino mice...
March 2018: International Journal of Toxicology
https://www.readbyqxmd.com/read/29546691/cabergoline-versus-bromocriptine-for-the-treatment-of-giant-prolactinomas-a-quantitative-and-systematic-review
#20
Hai Yan Huang, Shao Jian Lin, Wei Guo Zhao, Zhe Bao Wu
The aim of this study is to compare the efficacy of bromocriptine (BRC) versus cabergoline (CAB) in patients with giant prolactinomas. We searched MEDLINE, EMBASE, CENTRAL and Clinical Trials.gov for studies dated before March 1st, 2016, that used BRC or CAB for the treatment of patients with giant prolactinomas. Specific eligibility criteria were set to identify articles and cases. The selected articles were reviewed, and the data were extracted for analysis. The compared outcomes included tumor shrinkage, tumor response, normalization of prolactin (PRL) level, and visual field defect (VFD) improvement...
June 2018: Metabolic Brain Disease
keyword
keyword
113789
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"